Is PFAS exposure associated with oxidative stress, endocrine and metabolic disruption, and liver and kidney transport burden?

Per- and polyfluoroalkyl substances (PFAS) are highly persistent environmental chemicals whose unique chemical properties significantly impact human physiological systems.

Clinical and metabolic impacts

• Oxidative stress and metabolic disruption: Ample epidemiological and toxicological evidence links major legacy PFAS compounds (including PFOS, PFOA, PFNA, and PFHxS) to systemic oxidative stress. Human studies consistently show elevated markers of lipid peroxidation (malondialdehyde and 8-iso-PGF2a) and oxidative DNA damage (8-OHdG).
• Endocrine and glycemic alterations: PFAS exposure is associated with insulin resistance—reflected in elevated HOMA-IR and triglyceride-glucose indices—and an increased risk of type 2 diabetes. These compounds mirror fatty acids to activate PPAR-alpha, disrupting systemic lipid and amino acid metabolism.

Mechanistic pathways of persistence

• Resistance to metabolism: PFAS compounds completely resist hepatic enzymatic degradation due to their exceptionally stable carbon-fluorine (C-F) bonds, preventing standard phase I and II biotransformation.
• Protein binding and transport burden: Instead of being metabolized, over 98% of circulating PFAS binds to human serum albumin (HSA). The remaining unbound fraction (<2%) is filtered by the kidneys but undergoes intensive active tubular reabsorption back into the bloodstream via organic anion transporters (OATs).
• Tissue accumulation: This continuous active renal reabsorption, combined with hepatobiliary transport and enterohepatic recirculation, prevents rapid clearance. This constant recycling drives bioaccumulation and imposes a persistent functional transport burden on hepatic and renal filtration systems, correlating clinically with altered glomerular filtration rates (eGFR).

Bottom line

• PFAS exposure is strongly linked to oxidative stress and metabolic-endocrine disruption. Because their highly stable C-F bonds resist enzymatic metabolism and drive >98% protein binding, these compounds are continuously recycled via renal OATs and enterohepatic pathways, imposing a chronic transport and filtration burden on both the liver and kidneys.